Sanofi has acquired Zentiva Slovakia
December 2011 — The public shareholders of Zentiva Slovakia have sold approximately a 3% stake in the company to Sanofi, in a share buyback transaction. Financial details have not been disclosed.
Sanofi is a global and diversified healthcare leader which researches, develops and distributes therapeutic solutions focused on patients’ needs. The company has core strengths in healthcare, with six growth platforms: emerging markets, vaccines, consumer healthcare, diabetes treatments, innovative products and animal health.
Zentiva Slovakia is a producer of pharmaceutical products. Its product range consists of approximately 270 references in 500 pharmaceutical presentations, of which 180 are bound by prescription and 100 are OTC preparations or food supplements. The company focuses on the treatment of cardiovascular disorders, inflammatory conditions, pain, infections and diseases of the central nervous system and the gastrointestinal and urinary tracts. It also offers over-the-counter medicines and dietary supplements. It offers a range of therapeutic areas. In addition to generic drugs, Zentiva Slovakia also produces cosmetics and pharmaceutical substances.
Our role in the transaction
Oaklins' team in Slovakia acted as financial advisor to the buyer in this transaction.
Talk to the deal team
Related deals
UKAT Group has acquired Bayberry Limited
UK Addiction Treatment (UKAT) Group, a leading UK provider of residential addiction, mental health and behavioral health treatment backed by Sullivan Street Partners, has acquired Bayberry Limited, a specialist mental health and wellbeing treatment provider. Joining UKAT enables Bayberry to preserve continuity of care for patients and referral partners, retain the strength of its clinical team and benefit from UKAT’s operational infrastructure, referral network and marketing channels. This partnership supports Bayberry’s next stage of development while preserving the qualities that differentiate its service offering.
Learn moreMedicija has acquired Saulės Šeimos Medicinos Centras
Medicija has acquired a 100% stake in Saulės Šeimos Medicinos Centras.
Learn moreQuimpharma has completed the divestiture of a product portfolio to Megalabs
Quimpharma has completed the divestiture of a product portfolio to Megalabs México.
Learn more